# US 2013/0296324 A1 · Novel compositions comprising a phosphodiesterase-5 inhibitor and their use in methods of treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0296324 A1
- Document ID: US20130296324A1
- Status: Published application
- Kind: A1
- Application number: 13/776,166
- Filed: 2013-02-25
- Published: 2013-11-07
- Earliest claimed: 2007-05-18
- Assignees: Vivus, Inc.
- Inventors: Jerry M. Held
- Web page: https://patentgrep.com/patent/US20130296324A1

## CPC

- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/15: Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) {; Imines (C—N=C)}
- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates generally to novel pharmaceutical methods for the treatment of various conditions. Compositions comprising: at least one phosphodiesterase-5-inhibitor in combination with one or more of the following medications: a selective serotonin reuptake inhibitor; a serotonin-norepinephrine reuptake inhibitor; a cholinesterase inhibitor; a dopamine agonist; or a medication suitable to increase the chemical concentrations of the neurotransmitters, selected from amino acids, monoamines, neuropeptides and other agents capable of primary neurotransmission in the synaptic clefts, and their use for treating a neurodegenerative disease in a subject. The invention also relates to: Compositions comprising: at least one phosphodiesterase-5-inhibitor in combination with one or more of the following medications: a selective serotonin reuptake inhibitor; or a cholinesterase inhibitor, and their use for treating damaged skin in a subject.

## Claims

### Claim 1

A composition for treating a neurodegenerative disease in a subject comprising: at
least one phosphodiesterase-5 inhibitor in combination with one or more of the following medications:
a selective serotonin reuptake inhibitor;
a serotonin-norepinephrine reuptake inhibitor;
a cholinesterase inhibitor;
a dopamine agonist; or
a medication suitable to increase the chemical concentrations of other neurotransmitters, selected from amino acids, monoamines, neuropeptides and other agents capable of primary neurotransmission in the synaptic clefts.

### Claim 2 (depends on 1)

The composition of claim 1, comprising at least one phosphodiesterase-5 inhibitor selected from the group consisting of tadalafil, vardenafil and sildenafil.

### Claim 3 (depends on 1)

The composition of claim 1, comprising at least one selective serotonin reuptake inhibitor selected from the group consisting of fluvoxamine, paroxetine, citalopram, sertraline and paroxetine.

### Claim 4 (depends on 1)

The composition of claim 1, comprising at least one serotonin-norepinephrine reuptake inhibitor selected from the group consisting of reboxatine venlafaxine and duloxetine.

### Claim 5 (depends on 1)

The composition of claim 1, comprising at least one cholinesterase inhibitor selected from the group consisting of tacrine and donepezil.

### Claim 6 (depends on 1)

The composition of claim 1, comprising at least one dopamine agonist selected from the group consisting of bromocryptine, carbidopa/levodopa and pramipexole.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the medication suitable to increase the chemical concentrations of other neurotransmitters is selected from the group consisting of epinephrine, norepinephrine, dopamine, serotonin, melatonin, glutamic acid, gamma aminobutyric acid, aspartic acid, glycine, adenosine, ATP, GTP, vasopressin, somatostatin, neurotensin, leuteinizing hormone, insulin, histamine, nitrogen monoxide, carbon monoxide, acetylcholine. octopamine, tyramine, gastrin, cholecystokinin, oxytocin, neurophysin I, neurophysin II, neuropeptides Y, pancreatic polypeptide, peptide YY, corticotrophin, dynorphin, endorphin, enkephaline, secretin, motilin, glucagons, vasoactive intestinal peptide, growth hormone releasing factor, neurokinin A, neurokinin B, substance P, bombesin, gastrin releasing peptide, and anandamide.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the medications are administered individually.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the medications are in a combined from selected from the following:
a once-weekly patch;
a monthly patch;
a long-term injection;
a combined pill; and
an implant.

### Claim 10

A method of treating neurodegenerative disease in a subject in need thereof comprising administering to the subject a pharmaceutically acceptable amount of a phosphodiesterase-5 inhibitor (PI-5) and one or more of the following medications:
a selective serotonin reuptake inhibitor;
a serotonin-norepinephrine reuptake inhibitor;
a cholinesterase inhibitor;
a dopamine agonist; or
any suitable medication to increase the chemical concentrations of other neurotransmitters selected from amino acids, monoamines, neuropeptides and other agents capable of primary neurotransmission in the synaptic clefts.

### Claim 11 (depends on 10)

The method of claim 10, wherein the medications are formulated to be administered separately.

### Claim 12 (depends on 10)

The method of claim 10, wherein the medications are formulated to be administered in the same composition.

### Claim 13 (depends on 10)

The method of claim 10, wherein the neurodegenerative disease is Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, fronto-temporal dementia with Parkinson's features, progressive supranuclear palsies, essential dyskinesias, or dementia.

### Claim 14 (depends on 13)

The method of claim 13, wherein the disease is Alzheimer's disease.

### Claim 15 (depends on 13)

The method of claim 13, wherein the disease is Parkinson's disease.

### Claim 16 (depends on 13)

The method of claim 13, wherein the disease is multiple sclerosis.

### Claim 17 (depends on 13)

The method of claim 13, wherein the disease is amyotrophic lateral sclerosis.

### Claim 18 (depends on 13)

The method of claim 13, wherein the disease is fronto-temporal dementia with Parkinson's features.

### Claim 19 (depends on 13)

The method of claim 13, wherein the disease is progressive supranuclear palsies essential dyskinesias or dementia.

### Claim 20 (depends on 13)

The method of claim 13, wherein the disease is essential dyskinesias or dementia.

### Claim 21 (depends on 13)

The method of claim 13, wherein the disease is dementia.

### Claim at position 22

22-59. (canceled)
